品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
阿拉丁 | T126362-10mg | 10mg | 现货 | 97322-87-7 |
曲格列酮 Troglitazone |
Moligand™, ≥96% |
|
|
阿拉丁 | T126362-50mg | 50mg | 现货 | 97322-87-7 |
曲格列酮 Troglitazone |
Moligand™, ≥96% |
|
|
阿拉丁 | T126362-100mg | 100mg | 现货 | 97322-87-7 |
曲格列酮 Troglitazone |
Moligand™, ≥96% |
|
|
阿拉丁 | T427185-1ml | 1ml | 现货 | 97322-87-7 |
Troglitazone Troglitazone |
Moligand™, 10mM in DMSO |
|
|
麦克林 | T864205-10mg | 10mg | 订前询问 | 97322-87-7 |
Troglitazone Troglitazone |
≥96% |
|
|
麦克林 | T864205-50mg | 50mg | 订前询问 | 97322-87-7 |
Troglitazone Troglitazone |
≥96% |
|
|
罗恩 | R024506-10mg | 10mg | 现货 | 97322-87-7 |
曲格列酮 Troglitazone |
96% |
|
|
罗恩 | R024506-50mg | 50mg | 现货 | 97322-87-7 |
曲格列酮 Troglitazone |
96% |
|
|
MARY | MR135617-10mg | 10mg | 订前咨询 | 97322-87-7 |
曲格列酮 Troglitazone |
96% |
|
|
MARY | MR135617-50mg | 50mg | 订前咨询 | 97322-87-7 |
曲格列酮 Troglitazone |
96% |
|
|
源叶 | S81177-5mg | 5mg | 现货 | 97322-87-7 |
Troglitazone 5-(4-((6-hydroxy-2,5,7,8-tet... |
96% |
|
|
源叶 | S81177-10mg | 10mg | 期货,请咨询 | 97322-87-7 |
Troglitazone 5-(4-((6-hydroxy-2,5,7,8-tet... |
96% |
|
|
源叶 | S81177-50mg | 50mg | 现货 | 97322-87-7 |
Troglitazone 5-(4-((6-hydroxy-2,5,7,8-tet... |
96% |
|
|
源叶 | S81177-100mg | 100mg | 期货,请咨询 | 97322-87-7 |
Troglitazone 5-(4-((6-hydroxy-2,5,7,8-tet... |
96% |
|
|
源叶 | T94663-1ml | 1ml | 期货,请咨询 | 97322-87-7 |
Troglitazone Troglitazone |
10mM in DMSO |
|
|
毕得 | BD155994-10mg | 10mg | 现货 | 97322-87-7 |
5-[[4-[(3,4-二氢-6-羟基-2,5,7,8-... 5-(4-((6-Hydroxy-2,5,7,8-tet... |
98% |
|
|
毕得 | BD155994-50mg | 50mg | 现货 | 97322-87-7 |
5-[[4-[(3,4-二氢-6-羟基-2,5,7,8-... 5-(4-((6-Hydroxy-2,5,7,8-tet... |
98% |
|
|
毕得 | BD155994-100mg | 100mg | 现货 | 97322-87-7 |
5-[[4-[(3,4-二氢-6-羟基-2,5,7,8-... 5-(4-((6-Hydroxy-2,5,7,8-tet... |
98% |
|
|
毕得 | BD155994-25mg | 25mg | 现货 | 97322-87-7 |
5-[[4-[(3,4-二氢-6-羟基-2,5,7,8-... 5-(4-((6-Hydroxy-2,5,7,8-tet... |
98% |
|
|
毕得 | BD155994-250mg | 250mg | 现货 | 97322-87-7 |
5-[[4-[(3,4-二氢-6-羟基-2,5,7,8-... 5-(4-((6-Hydroxy-2,5,7,8-tet... |
98% |
|
|